BVXV Annual SG&A
$5.30 M
-$2.33 M-30.54%
31 December 2022
Summary:
As of February 5, 2025, BVXV annual selling, general & administrative expenses is $5.30 million, with the most recent change of -$2.33 million (-30.54%) on December 31, 2022. During the last 3 years, it has risen by +$2.59 million (+96.05%).BVXV Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV Quarterly SG&A
$1.14 M
-$50.00 K-4.20%
30 June 2023
Summary:
As of February 5, 2025, BVXV quarterly selling, general & administrative expenses is $1.14 million, with the most recent change of -$50.00 thousand (-4.20%) on June 30, 2023. Over the past year, it has dropped by -$148.00 thousand (-11.48%).BVXV Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV TTM SG&A
-$465.84 M
-$11.64 M-2.56%
30 June 2023
Summary:
As of February 5, 2025, BVXV TTM selling, general & administrative expenses is -$465.84 million, with the most recent change of -$11.64 million (-2.56%) on June 30, 2023. Over the past year, it has dropped by -$472.78 million (-6804.90%).BVXV TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.5% | -11.5% | -6804.9% |
| 3 y3 years | +96.0% | -5.0% | -10000.0% |
| 5 y5 years | +287.6% | +188.9% | -10000.0% |
BVXV Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -30.5% | -50.0% | -6065.1% |
BiondVax Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $1.14 M(-4.2%) | $5.13 M(-2.8%) |
| Mar 2023 | - | $1.19 M(-35.8%) | $5.27 M(-4.7%) |
| Dec 2022 | $5.30 M(-30.5%) | $1.86 M(+97.9%) | $5.53 M(-7.1%) |
| Sept 2022 | - | $937.70 K(-27.3%) | $5.96 M(-14.2%) |
| June 2022 | - | $1.29 M(-11.2%) | $6.95 M(-11.0%) |
| Mar 2022 | - | $1.45 M(-36.3%) | $7.81 M(+3.3%) |
| Dec 2021 | $7.63 M(+51.9%) | $2.28 M(+18.5%) | $7.56 M(+12.9%) |
| Sept 2021 | - | $1.93 M(-10.5%) | $6.69 M(-2.8%) |
| June 2021 | - | $2.15 M(+79.3%) | $6.88 M(+16.0%) |
| Mar 2021 | - | $1.20 M(-15.3%) | $5.93 M(+18.5%) |
| Dec 2020 | $5.02 M(+85.8%) | $1.42 M(-33.2%) | $5.01 M(+32.3%) |
| Sept 2020 | - | $2.12 M(+76.4%) | $3.79 M(+53.4%) |
| June 2020 | - | $1.20 M(+337.1%) | $2.47 M(-2.5%) |
| Mar 2020 | - | $274.70 K(+43.1%) | $2.53 M(-4.5%) |
| Dec 2019 | $2.70 M(+99.9%) | $192.00 K(-76.0%) | $2.65 M(-3.9%) |
| Sept 2019 | - | $800.90 K(-36.6%) | $2.76 M(+16.6%) |
| June 2019 | - | $1.26 M(+220.1%) | $2.37 M(+58.1%) |
| Mar 2019 | - | $395.00 K(+32.5%) | $1.50 M(+10.6%) |
| Dec 2018 | $1.35 M | $298.20 K(-27.0%) | $1.35 M(-1.5%) |
| Sept 2018 | - | $408.30 K(+3.4%) | $1.37 M(-10.9%) |
| June 2018 | - | $395.00 K(+56.9%) | $1.54 M(+17.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $251.70 K(-20.9%) | $1.31 M(-3.7%) |
| Dec 2017 | $1.37 M(+29.5%) | $318.40 K(-44.8%) | $1.36 M(+1.1%) |
| Sept 2017 | - | $576.80 K(+253.6%) | $1.35 M(+28.4%) |
| June 2017 | - | $163.10 K(-46.0%) | $1.05 M(-8.4%) |
| Mar 2017 | - | $301.90 K(-0.7%) | $1.14 M(+9.4%) |
| Dec 2016 | $1.05 M(+26.2%) | $304.10 K(+8.8%) | $1.05 M(+3.2%) |
| Sept 2016 | - | $279.40 K(+7.8%) | $1.01 M(+3.4%) |
| June 2016 | - | $259.10 K(+27.1%) | $981.00 K(+11.4%) |
| Mar 2016 | - | $203.90 K(-25.1%) | $880.60 K(+4.7%) |
| Dec 2015 | $836.10 K(+29.4%) | $272.10 K(+10.7%) | $841.00 K(+11.1%) |
| Sept 2015 | - | $245.90 K(+54.9%) | $757.00 K(+14.1%) |
| June 2015 | - | $158.70 K(-3.4%) | $663.30 K(-1.3%) |
| Mar 2015 | - | $164.30 K(-12.7%) | $671.80 K(+1.0%) |
| Dec 2014 | $646.10 K(+9.9%) | $188.10 K(+23.6%) | $665.40 K(+7.8%) |
| Sept 2014 | - | $152.20 K(-9.0%) | $617.50 K(+0.6%) |
| June 2014 | - | $167.20 K(+5.9%) | $614.10 K(+37.4%) |
| Mar 2014 | - | $157.90 K(+12.6%) | $446.90 K(+54.6%) |
| Dec 2013 | $588.10 K(-6.8%) | $140.20 K(-5.8%) | $289.00 K(+94.2%) |
| Sept 2013 | - | $148.80 K | $148.80 K |
| Dec 2012 | $630.90 K(+5.6%) | - | - |
| Dec 2011 | $597.20 K | - | - |
FAQ
- What is BiondVax Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals annual SG&A year-on-year change?
- What is BiondVax Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals quarterly SG&A year-on-year change?
- What is BiondVax Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals TTM SG&A year-on-year change?
What is BiondVax Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of BVXV is $5.30 M
What is the all time high annual SG&A for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high annual selling, general & administrative expenses is $7.63 M
What is BiondVax Pharmaceuticals annual SG&A year-on-year change?
Over the past year, BVXV annual selling, general & administrative expenses has changed by -$2.33 M (-30.54%)
What is BiondVax Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of BVXV is $1.14 M
What is the all time high quarterly SG&A for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $2.28 M
What is BiondVax Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, BVXV quarterly selling, general & administrative expenses has changed by -$148.00 K (-11.48%)
What is BiondVax Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of BVXV is -$465.84 M
What is the all time high TTM SG&A for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high TTM selling, general & administrative expenses is $7.81 M
What is BiondVax Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, BVXV TTM selling, general & administrative expenses has changed by -$472.78 M (-6804.90%)